Prosensa Awarded Best Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards

Leiden, The Netherlands, Nov. 15, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has been awarded Best Biotech Pipeline 2013 in the Rare & Orphan Advocacy and Research (ROAR) Awards.
The ROAR Awards were announced during the 4th Annual World Orphan Drug Congress Europe, November 14-15, 2013, in Geneva, Switzerland. The inaugural 2013 awards are an opportunity to recognize and honor achievements by organizations and individuals from industry, patient, and rare disease advocacy communities.
“There is a desperate unmet need in rare diseases, and we are dedicated to developing treatments for patients who face very limited options,” said Hans Schikan, CEO of Prosensa. “We are honored to accept this award and would like to thank the judging committee for recognizing our efforts, and our many partners and advocates for their steadfast support.”
The Best Biotech Pipeline Award recognizes the breadth and depth of the company’s orphan drug pipeline, most notably its pioneering work in Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease.

Leave a comment

Your email address will not be published. Required fields are marked *